Insulin-Like Growth Factors (IGF) and IGF-Binding Proteins (IGFBP) in the Serum of Patients with Ovarian Tumors

Abstract

IGF-1, IGF-2, and IGFBP-1,2,3 were assayed in blood serum of patients with malignant ovarian tumors (n=44), borderline ovarian tumors (n=11), and benign ovarian tumors (n=12) as well as in healthy women (n=33). In blood serum of patients with malignant ovarian tumors, the level of IGF-1 was lower and IGFBP-1 was higher than in other groups. In patients with malignant and borderline ovarian tumors, the level of IGFBP-2 was higher than in healthy women and in patients with benign ovarian tumors. There was no correlation between most examined parameters and the clinical and morphological peculiarities of ovarian tumors. The study revealed IGF/IGFBP imbalance in patients with malignant ovarian tumor and showed that IGFBP-2 proved to be a potential diagnostic serological marker w with 90% sensitivity and 90% specificity.

The NF‐κB‐modulated miR‐19a‐3p enhances malignancy of human ovarian cancer cells through inhibition of IGFBP‐3 expression

“…To further know how miR‐19a‐3p regulates the oncogenesis of ovarian cancer cells, we predicted the potential downstream targets of miR‐19a‐3p by the algorithms of TargetScan and PicTar. Among the potential targets, IGFBP‐3 was selected for further study because it is a well‐known tumor suppressor and it is downregulated in patients with malignant ovarian cancer …”

“…Among the potential targets, IGFBP-3 was selected for further study because it is a well-known tumor suppressor and it is downregulated in patients with malignant ovarian cancer. 28 Base-pairing complementation showed that the 3′ untranslated region (UTR) of IGFBP-3 contains a putative site that is conserved among species and the site has significant complementarity with the seed sequence of miR-19a-3p ( Figure 5A). We next examined the interaction between miR-19a-3p and 3′-UTR of IGFBP3 mRNA by the dual-luciferase reporter assay.…”

Insulin-Like Growth Factor Binding Proteins in Autoimmune Diseases

“…Recent studies also validated IGFBPs' role in the diagnosis and prognosis prediction in some solid tumor including nasopharyngeal carcinoma, ovarian cancer, pancreatic cancer, etc. (42–46). Despite the huge development of IGFBPs as biomarkers in cancer, there have been a number of studies focusing on the utility of IGFBPs as biomarkers in autoimmune diseases (Table 1).…”

Expression of Insulin-Like Growth Factor Binding Protein-5 (IGFBP5) Reverses Cisplatin-Resistance in Esophageal Carcinoma

“…Inhibition of IGF signaling by IGFBP3 was shown to result in increased sensitivity to CDDP in CDDP-resistant lung cancer cells [ 8 ]. In spite of the fact that many studies have characterized the roles of six IGFBPs (IGFBP1-6) in the IGF signaling pathway [ 10 , 11 , 12 ], studies on the acquisition of CDDP-resistance mediated by IGFBPs are scanty. Moreover, other candidate proteins have also been reported to be involved in tumor growth and/or therapeutic responses; examples include, but not limited to, insulin-like growth factor binding protein 5 (IGFBP5) [ 13 ], major histocompatibility complex, class II, DQ alpha 2 (HLA-DQA2), [ 14 ] carboxypeptidase E (PE) [ 15 ], and PLXDC2 (CDNAFLJ45742fis) [ 16 ].…”